- f
Supplementary file 2_Prevalence of tuberculosis among People Who Use Drugs...
- figshare.com
docxUpdated Oct 3, 2025+ more versions
Share
Facebook
Twitter
EmailClick to copy linkLink copiedCiteW. S. Ngowi; O. O. Mandizadza; Minyan Wang; W. T. Shao; Conghua Ji (2025). Supplementary file 2_Prevalence of tuberculosis among People Who Use Drugs 2000–2024: a systematic review and meta-analysis.docx [Dataset]. http://doi.org/10.3389/fpubh.2025.1635053.s002docxAvailable download formatsUnique identifierhttps://doi.org/10.3389/fpubh.2025.1635053.s002Dataset updatedOct 3, 2025Dataset provided byFrontiersAuthorsW. S. Ngowi; O. O. Mandizadza; Minyan Wang; W. T. Shao; Conghua JiLicenseAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automaticallyDescriptionBackgroundPeople who use drugs (PWUD) are at a higher risk of developing tuberculosis (TB); however, there is no clear evidence to determine the prevalence of TB in this group accurately. This study aimed to systematically review the prevalence of tuberculosis (TB) among PWUD across studies conducted in different countries.MethodsAn electronic search for original articles on the prevalence of TB among People Who Use Drugs (PWUD) was conducted in PubMed, Web of Science, and Science Direct. The reference lists of included studies were manually screened to identify omitted eligible studies. Extracted data were imported into a Microsoft Excel sheet. The random-effects model was employed to estimate the pooled prevalence of TB among People Who Use Drugs (PWUD), with effect size (ES) reported as point estimates and 95% confidence interval (CI). Subgroup analysis and sensitivity tests were also performed. All analyses were performed in STATA version 18.ResultsA total of 2,085 articles were retrieved from the search. After removing duplicates, screening titles and abstracts, and excluding non-eligible articles, 23 studies involving 164,121 patients met the inclusion criteria for the analysis. The average estimated prevalence of tuberculosis among People Who Use Drugs (PWUD) was 25% (95% CI: 0.21, 0.35). The prevalence of tuberculosis among PWUD was higher in Asia (32%) and North America (28%) compared to South America (10%) and Africa (5%). Additionally, the average prevalence of tuberculosis among PWUD was 36% in case-control studies, 26% in cohort studies, and 23% in cross-sectional studies.ConclusionThis review highlighted a high pooled prevalence of tuberculosis among People Who Use Drugs (PWUD), which varies across continents, study types, drug categories, and assessment tools. This emphasizes the need to integrate screening and prevention strategies into programs for PWUDs, address systemic inequities to reduce transmission, improve data reporting, and conduct more research in under-reported regions such as Africa and South Asia.Systematic review registrationidentifier CRD42024564181.
- w
Global Rare Hemophilia Factor Databank Market Research Report: By Type of...
- wiseguyreports.com
Updated Sep 15, 2025+ more versionsShareFacebookTwitterEmailClick to copy linkLink copiedCite(2025). Global Rare Hemophilia Factor Databank Market Research Report: By Type of Hemophilia Factor (Factor VIII, Factor IX, Factor XI, Factor VII, Factor XIII), By Application (Clinical Research, Genetic Testing, Drug Development, Patient Management), By Data Source (Genetic Database, Clinical Trials, Patient Registries, Research Publications), By End User (Healthcare Providers, Pharmaceutical Companies, Research Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035 [Dataset]. https://www.wiseguyreports.com/reports/rare-hemophilia-factor-databank-marketDataset updatedSep 15, 2025Licensehttps://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
Time period coveredSep 25, 2025Area coveredGlobalDescriptionBASE YEAR 2024 HISTORICAL DATA 2019 - 2023 REGIONS COVERED North America, Europe, APAC, South America, MEA REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends MARKET SIZE 2024 2113.7(USD Million) MARKET SIZE 2025 2263.7(USD Million) MARKET SIZE 2035 4500.0(USD Million) SEGMENTS COVERED Type of Hemophilia Factor, Application, Data Source, End User, Regional COUNTRIES COVERED US, Canada, Germany, UK, France, Russia, Italy, Spain, Rest of Europe, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Rest of APAC, Brazil, Mexico, Argentina, Rest of South America, GCC, South Africa, Rest of MEA KEY MARKET DYNAMICS rising prevalence of hemophilia, increasing research funding, advancements in treatment options, growing demand for data analytics, regulatory compliance pressures MARKET FORECAST UNITS USD Million KEY COMPANIES PROFILED Octapharma, Sobi, Grifols, Amgen, Sanofi, Roche, Baxter International, Pfizer, Novo Nordisk, Bayer, BristolMyers Squibb, Hemophilia Health Services, Takeda Pharmaceutical, CSL Behring, Boehringer Ingelheim MARKET FORECAST PERIOD 2025 - 2035 KEY MARKET OPPORTUNITIES Increasing gene therapy advancements, Rising demand for personalized medicine, Expanding global awareness campaigns, Growth in rare disease funding, Enhanced data analytics technology COMPOUND ANNUAL GROWTH RATE (CAGR) 7.1% (2025 - 2035) 
Not seeing a result you expected?
Learn how you can add new datasets to our index.
FacebookTwitterEmailSupplementary file 2_Prevalence of tuberculosis among People Who Use Drugs 2000–2024: a systematic review and meta-analysis.docx
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
BackgroundPeople who use drugs (PWUD) are at a higher risk of developing tuberculosis (TB); however, there is no clear evidence to determine the prevalence of TB in this group accurately. This study aimed to systematically review the prevalence of tuberculosis (TB) among PWUD across studies conducted in different countries.MethodsAn electronic search for original articles on the prevalence of TB among People Who Use Drugs (PWUD) was conducted in PubMed, Web of Science, and Science Direct. The reference lists of included studies were manually screened to identify omitted eligible studies. Extracted data were imported into a Microsoft Excel sheet. The random-effects model was employed to estimate the pooled prevalence of TB among People Who Use Drugs (PWUD), with effect size (ES) reported as point estimates and 95% confidence interval (CI). Subgroup analysis and sensitivity tests were also performed. All analyses were performed in STATA version 18.ResultsA total of 2,085 articles were retrieved from the search. After removing duplicates, screening titles and abstracts, and excluding non-eligible articles, 23 studies involving 164,121 patients met the inclusion criteria for the analysis. The average estimated prevalence of tuberculosis among People Who Use Drugs (PWUD) was 25% (95% CI: 0.21, 0.35). The prevalence of tuberculosis among PWUD was higher in Asia (32%) and North America (28%) compared to South America (10%) and Africa (5%). Additionally, the average prevalence of tuberculosis among PWUD was 36% in case-control studies, 26% in cohort studies, and 23% in cross-sectional studies.ConclusionThis review highlighted a high pooled prevalence of tuberculosis among People Who Use Drugs (PWUD), which varies across continents, study types, drug categories, and assessment tools. This emphasizes the need to integrate screening and prevention strategies into programs for PWUDs, address systemic inequities to reduce transmission, improve data reporting, and conduct more research in under-reported regions such as Africa and South Asia.Systematic review registrationidentifier CRD42024564181.